Biopharmaceutical company Amgen is ending voluntary 340B pricing on orphan drugs for certain 340B hospital covered entities effective Jan. 1. | Source: Shutterstock
Amgen Ending 340B-Like Price Reductions on Orphan Drugs on Jan. 1 (Updated)
UPDATE Wednesday Dec. 9, 2020, 4:30 p.m. EST—An Amgen spokesperson provided the following policy clarification late this afternoon:
Amgen is clarifying and confirming that children’s hospitals will not be impacted by the change in policy regarding voluntary discounts to certain ACA-expansion entities. Any children’s hospitals that erroneously received a letter will be receiving a clarifying communication from Amgen.